LogoThe Incretin Space
Login
Subscribe
LogoThe Incretin Space

GLP-1

Insulin lever to 11

GLP-1

+1

What is the deal with liver concerns in small molecule GLP-1s?

Jul 16, 2026

•

10 min read

What is the deal with liver concerns in small molecule GLP-1s?

A guest post by Jen Can NuSH on liver concerns and small molecule GLP1 medications

David W
JenCanNuSH
David W, +1

GLP-1

+3

ADA Conference 2026: Zenagamtide, Berobenatide, UBT251, enicepatide & orforglipron

Jul 2, 2026

•

14 min read

ADA Conference 2026: Zenagamtide, Berobenatide, UBT251, enicepatide & orforglipron

Orals, Triples, Biologics and even more data from ADA 2026

David W
David W

GLP-1

+4

Eloralintide + Tirzepatide = Bariatric Surgery results!

Jul 1, 2026

•

5 min read

Eloralintide + Tirzepatide = Bariatric Surgery results!

New phase 1b data shows incredible weight loss

David W
David W

GLP-1

+2

ADA Conference 2026: CagriSema & Survodutide

Jun 19, 2026

•

18 min read

ADA Conference 2026: CagriSema & Survodutide

A tale of dual agonists, glucagon or amylin, who wins the insulin sensitivity race?

David W
David W

GLP-1

+3

ADA 2026: Retatrutide Revolution

Jun 9, 2026

•

12 min read

ADA 2026: Retatrutide Revolution

A paradigm shift in diabetes and obesity arrives!

GLP-1

+6

ADA Conference 2026 Preview

May 29, 2026

•

10 min read

ADA Conference 2026 Preview

The Super Bowl Conference for diabetes and incretins!

GLP-1

+3

Triumphant! Retatrutide matches bariatric surgery outcomes

May 21, 2026

•

4 min read

Triumphant! Retatrutide matches bariatric surgery outcomes

Triumph 1 trial led to 19-30% weight loss depending on dose and time on trial.

GLP-1

Taming the fires

Apr 30, 2026

•

9 min read

Taming the fires

The anti-inflammatory benefits of GLP-1 explored

GLP-1

+1

ACHIEVEment Unlocked!

Apr 16, 2026

•

2 min read

ACHIEVEment Unlocked!

Orforglipron reduces the risk of cardiovascular events and all cause death in diabetic patients

GLP-1

+3

Retatrutide TRANSCENDS diabetes in first phase 3 trial

Mar 19, 2026

•

7 min read

Retatrutide TRANSCENDS diabetes in first phase 3 trial

A shift in what's possible for diabetes and obesity

GLP-1

+2

More amylin updates & more tolerable drugs(finally)?

Mar 11, 2026

•

11 min read

More amylin updates & more tolerable drugs(finally)?

More early trial results from some new players in the obesity medicine space

GLP-1

+5

GLP-1 and the kidneys

Dec 16, 2025

•

40 min read

GLP-1 and the kidneys

Incretins are changing the narrative of chronic kidney disease

GLP-1

+3

First Retatrutide phase 3 data, a Triumph of Science!

Dec 11, 2025

•

10 min read

First Retatrutide phase 3 data, a Triumph of Science!

Bariatric surgery in a shot! It might be too effective?! And what's dysesthesia?

GLP-1

Structuring a better mousetrap, aleniglipron

Dec 8, 2025

•

9 min read

Structuring a better mousetrap, aleniglipron

Small molecule, flashy results, is it too late to the party?

GLP-1

+2

Obesity Week 2025 Medications

Nov 14, 2025

•

31 min read

Obesity Week 2025 Medications

Orforglipron, HRS 9531, MET-097, Eloralintide and Mazdutide, OH MY!

GLP-1

+1

GIP: The gentle & sensitive incretin

Sep 5, 2025

•

13 min read

GIP: The gentle & sensitive incretin

Less nausea, more insulin sensitivity, and a little less inflammation Part 2 in a series on GIP

GLP-1

+2

GIP: The unsung incretin

Jul 29, 2025

•

15 min read

GIP: The unsung incretin

The master incretin of the alpha and beta cell starts to shinePart 1 in a series on GIP

GLP-1

+1

ADA Conference 2025: Orforglipron & Bimagrumab

Jun 26, 2025

•

9 min read

ADA Conference 2025: Orforglipron & Bimagrumab

Lilly's oral non-peptide GLP-1 could change everything & bimagrumab flexes its muscle, but at what cost?

GLP-1

+1

ADA Conference 2025: CagriSema

Jun 24, 2025

•

9 min read

ADA Conference 2025: CagriSema

Novo's Dual Amylin-GLP1 agonist shows promise but caveats apply

The Incretin Space

The Incretin Space

A collection of collated data on incretin drug developments, including new drugs, new treatments and the future of incretin in medicine


Home

© 2026 The Incretin Space.
beehiivPowered by beehiiv